AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters_老虎社区_美港股上老虎

AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters

CNBC2021-04-09

KEY POINTS Australia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

vxBull
·2021-04-09
Not worried
回复
3
举报
waihustle
·2021-04-09
When will the pandemic be over?
回复
3
举报
KaelynGoMoon
·2021-04-09
Like n comment pls
回复
5
举报
收起
- nujnay:
  pls comment back
  2021-04-09
  回复
  举报
- Jazling:
  Ok
  2021-04-10
  回复
  举报
benlwh
·2021-04-09
Oh good to know!
回复
1
举报
收起
- nujnay:
  👍🏻
  2021-04-09
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1102097181?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-04-09 21:17","share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","id":"1102097181","market":"uk","top_or_hot":-1,"title":"AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters","media":"CNBC","content":"<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">网页链接</a>\n\n</div>\n","source":"cnbc_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html","article_id":"1102097181","we_media_id":null,"thumbnails":[],"rights":{"source":"cnbc_highlight","url":"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.ArticleHeader-headline{#titleStyle#}a{#lv2TextColor#}.ArticleHeader-time, .Author-authorNameAndSocial a{#sourceStyle#;}","selectors":".PageBuilder-pageWrapper","filters":".ArticleHeader-eyebrow, .RelatedTags-relatedTags","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1102097181","pubTimestamp":1617974277,"columns":[],"sourceInfo":{"source_id":"cnbc_highlight","name":"CNBC"},"weMediaInfo":null,"summary":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or aband","collect":0,"end_time":0,"defaultTopTitle":"cnbc.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"translate_title":"阿斯利康：分析师指出尽管Covid疫苗紧张，但仍有前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"AZN.UK":0.9},"content_text":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\n\nControversy over AstraZeneca’s Covid-19 vaccine has sparked some investor concerns about its stock, according to Jefferies – but it’s not all bad news for the British pharmaceutical company.\nAustralia, the Philippines and the African Union have become the latest to either curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine. Both the U.K. and European medicines regulators (the MHRA and EMA, respectively), have emphasized that the benefits of the jab still outweigh the risks, but EU leaders have yet to agree on a joint policy regarding the shots.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\nThis despite the fact that the company has pledged that the vaccine will be not-for-profit for the “duration of the pandemic,” and will be offered on a non-profit basis in perpetuity to low and middle-income countries.\nThe overall blood clot risk has been estimated at around one in 250,000, and British policymakers and health experts have rushed to defend the vaccinein recent days.\nWelford noted that despite the company’s “remarkable successes” in gaining regulatory approval and ramping up manufacturing of its profit vaccine, the safety concerns raised in Europe are “top of mind for many generalists.”\n“We view FDA Emergency Use Authorization and agreements around dose distribution in U.K./EU as key to shift debate beyond the COVID-19 vaccine, albeit concerns it has been a distraction for management may linger,” he contended.\nThe vaccine has been approved for use in the U.K.,Europe and elsewhere, and hundreds of millions of doses have been ordered by countries across the world. However, it has not yet been granted emergency use authorization in the U.S.\nLooking beyond the shot, Jefferies upgraded AstraZeneca to buy in mid-march, pointing to its “compelling growth profile within EU pharma” and its relative discount based on the expected strategic benefits of its $37 billion acquisition of Alexion Pharmaceuticals, expected to close in the third quarter.\nWelford defended the move by highlighting that the company’s 15x estimated 2022 price-to-earnings ratio — a mechanism for determining whether a company’s stock is fairly valued — is similar to its peers, despite its “leading growth profile.”\nPromising pipeline\nAstraZeneca was trading at £7,337 per share on the London Stock Exchange Friday, and Jefferies has set a price target of £8,850. In Wednesday’s research note, Welford again pointed to multiple catalysts in the pipeline which could propel the stock higher in the coming months.\nPhase three trial data is expected for its breast cancer treatment enhertu is due in the second half of 2021, along with potential approvals for its anifrolumab drug to treat lupus. Jefferies also anticipates approvals for asthma drug tezepelumab in the first half of 2022 after “impressive” phase three data, and a long-delayed approval for anemia candidate roxadustat in the second half of 2021. Updated phase one and two data on lung cancer treatment datopotamab is also expected soon.\nIn a recent note, Morningstar Director of Healthcare Equity Research Damien Conover said of AstraZeneca, “the strong overall innovation seen with the vaccine and pipeline reinforces our conviction in the firm’s wide moat.”\nHe added that AstraZeneca was “making strides in targeting areas of unmet medical need,” projecting that phase three trial data for the company’s farxiga treatment for preserved heart failure was likely to result in approval for the medication.\nConover categorized anifrolumab as “higher risk of approval,” while roxadustat was deemed “medium risk” and tezepelumab “lower risk.”\n“Longer term, we are encouraged by the robustness of the company’s early-stage pipeline, and opportunities to create combinations with Farxiga look well positioned to treat several large cardiometabolic indications where unmet medical need remains high,” Conover said. He added that Morningstar also remains bullish on AstraZeneca’s pipeline for cancer drugs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":346065885,"gmtCreate":1617975593047,"gmtModify":1634295432692,"author":{"id":"3554974441390212","authorId":"3554974441390212","name":"vxBull","avatar":"https://static.tigerbbs.com/37cb77b20b35271b4b50c825da88849d","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3554974441390212","authorIdStr":"3554974441390212"},"htmlText":"Not worried","listText":"Not worried","text":"Not worried","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/346065885","repostId":1102097181,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":346069098,"gmtCreate":1617975244514,"gmtModify":1634295436347,"author":{"id":"3574772025886423","authorId":"3574772025886423","name":"waihustle","avatar":"https://static.tigerbbs.com/ff00b015a4bdda521053764de04de141","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3574772025886423","authorIdStr":"3574772025886423"},"htmlText":"When will the pandemic be over?","listText":"When will the pandemic be over?","text":"When will the pandemic be over?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/346069098","repostId":1102097181,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":346084079,"gmtCreate":1617975068291,"gmtModify":1634295437694,"author":{"id":"3577222624390363","authorId":"3577222624390363","name":"KaelynGoMoon","avatar":"https://static.tigerbbs.com/9b50f8ca0a8d2a4024495f1ca5401a45","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3577222624390363","authorIdStr":"3577222624390363"},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/346084079","repostId":1102097181,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3996493,"gmtCreate":1617975695595,"gmtModify":1635741560392,"authorId":3562385137512604,"author":{"id":3562385137512604,"idStr":"3562385137512604","authorId":3562385137512604,"name":"nujnay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":346084079,"type":1,"supId":0,"prevId":0,"content":"pls comment back","text":"pls comment back","html":"pls comment back"},{"id":4003651,"gmtCreate":1618058531115,"gmtModify":1635741104253,"authorId":3566821013640470,"author":{"id":3566821013640470,"idStr":"3566821013640470","authorId":3566821013640470,"name":"Jazling","avatar":"https://static.tigerbbs.com/85e0a83573d9307f57fca9b2baed72af","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":346084079,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":346089362,"gmtCreate":1617974682056,"gmtModify":1634295441226,"author":{"id":"3573964806596144","authorId":"3573964806596144","name":"benlwh","avatar":"https://static.tigerbbs.com/00e34173af580a6e71b56f222ea75c39","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573964806596144","authorIdStr":"3573964806596144"},"htmlText":"Oh good to know!","listText":"Oh good to know!","text":"Oh good to know!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/346089362","repostId":1102097181,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3996472,"gmtCreate":1617975596494,"gmtModify":1635741561917,"authorId":3562385137512604,"author":{"id":3562385137512604,"idStr":"3562385137512604","authorId":3562385137512604,"name":"nujnay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":346089362,"type":1,"supId":0,"prevId":0,"content":"👍🏻","text":"👍🏻","html":"👍🏻"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":20,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}